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Currently, there are very limited pharmaceutical interventions for Alzheimer’s disease
(AD) to alleviate the amyloid burden implicated in the pathophysiology of the disease.
Alzheimer’s disease is characterized immunohistologically by the accumulation of senile
plaques in the brain with afflicted patients progressively losing short-term memory and,
ultimately, cognition. Although significant improvements in clinical diagnosis and care for
AD patients have been made, effective treatments for this devastating disease remain
elusive. A key component of the amyloid burden of AD comes from accumulation of
the amyloid-beta (Aβ) peptide which comes from processing of the amyloid precursor
protein (APP) by enzymes termed secretases, leading to production of these toxic Aβ
peptides of 40–42 amino acids. New therapeutic approaches for reducing Aβ are warranted
after the most logical avenues of inhibiting secretase activity appear less than optimal in
ameliorating the progression of AD. Novel therapeutics may be gleaned from proteomics
biomarker initiatives to yield detailed molecular interactions of enzymes and their potential
substrates. Explicating the APPome by deciphering protein complexes forming in cells is
a complementary approach to unveil novel molecular interactions with the amyloidogenic
peptide precursor to both understand the biology and develop potential upstream drug
targets. Utilizing these strategies we have identified EC 3.4.24.15 (EP24.15), a zinc
metalloprotease related to neprilysin (NEP), with the ability to catabolize Aβ 1–42 by
examining first potential in silico docking and then verification by mass spectrometry.
In addition, a hormone carrier protein, transthyreitin (TTR), was identified and with its
abundance in cerebrospinal fluid (CSF), found to clear Aβ by inhibiting formation of
oligomeric forms of Aβ peptide. The confluence of complementary strategies may allow
new therapeutic avenues as well as biomarkers for AD that will aid in diagnosis, prognosis
and treatment.
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INTRODUCTION
Alzheimer’s disease is a terrible neurodegenerative disorder affect-
ing the elderly resulting in progressive mental decline with pro-
found effects on memory. Accumulating evidence indicates that
the failure to clear Aβ from the brain is a primary step in
the pathology of sporadic Alzheimer’s disease (AD; Crews and
Masliah, 2010). Many of the most potent gene polymorphisms
that confer risk for AD affect clearance of Aβ (Bu, 2009; Kim et al.,
2013; Reitz et al., 2013). This is underscored by the finding that
individuals with AD are deficient in Aβ clearance while the rate of
Aβ production is unaltered (Mawuenyega et al., 2010). It has long
been suspected that the disruption of Aβ catabolism is a critical
factor in Aβ accumulation (Mukherjee and Hersh, 2002).
Endopeptidases are peptidolytic enzymes that cleave pro-
teins at internal peptide bonds, and are extremely important
in synthetic and degradative neuropeptide metabolism. Direct
proteolysis by endopeptidases is a major pathway of Aβ clearance
and there are several enzymes that can cleave this peptide (Miners
et al., 2011; Nalivaeva et al., 2012). The usual suspects include
angiotensin converting enzyme (ACE), endothelin converting
enzymes (ECE), neprilysin (NEP) and insulin degrading enzyme
(IDE). While mice genetically deficient in ACE did not show
elevated levels of Aβ (Eckman et al., 2006; Hemming et al., 2007);
ACE may still be relevant in the human system as mutations in
the ACE gene have been linked to increased risk of AD (Bertram
and Tanzi, 2008). Mice deficient in ECE-1 or NEP show ele-
vated levels of the Aβ peptide (Iwata et al., 2001; Eckman et al.,
2003, 2006; Madani et al., 2006; Rodriguiz et al., 2008; Walther
et al., 2009), and some polymorphisms in these genes have been
associated with risk of developing AD (Marr and Spencer, 2010;
Pacheco-Quinto et al., 2013). Deficiencies in IDE also produce
elevated levels of Aβ in mice (Farris et al., 2003; Miller et al.,
2003) and mutations have been linked to AD risk (Kim et al.,
2007; Zhang et al., 2013). More recently, Neprilysin-2 (NEP2),
which has been demonstrated in vivo to control Aβ levels by
cleaving Aβ between amino acids Val18 and Leu17 similar to
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ECE-1 (Huang et al., 2008), is reduced in association with AD
(Huang et al., 2008, 2012; Hanson et al., 2010; Hafez et al.,
2011).
In addition to these endopeptidases, there are many other
factors that may contribute to Aβ clearance including enzymes
and carrier proteins (reviewed in Miners et al., 2011; Nalivaeva
et al., 2012; Leissring and Turner, 2013) (also see Marr and
Hafez, 2014 in press in this issue). Neuromics technology is the
proteomics of the neural systems and the brain in particular and
has advanced such that both known and novel interactors can
be identified without bias. The ability to isolate in vivo protein
complexes under close to physiological conditions reveals the
complexity of interactions that can be considered in the context
of systems biology (Gingras et al., 2005; Collins and Choudhary,
2008). The first interaction we have examined was the role of
novel proteases involved in Aβ clearance.
We have sought to discover new activities that can miti-
gate the effects of Aβ by utilizing this peptide as a substrate
for catabolism. One such peptidase has been EP24.15 (thimet
oligopeptidase, THOP; EC 3.4.24.15), an amyloid precursor pro-
tein (APP) interacting protein that has been chronicled in the
context of AD. EP24.15 is a soluble, 77 kD metalloendopeptidase
with extracellular peptide processing/degrading activity in the
family of zinc metallopeptidases that can promote the clearance
of Aβ. In the central nervous system EP24.15 is involved in
the catabolism of bioactive peptides including the generation
of enkephalins, and processing of other neuropeptides such as
bradykinin, gonadotropin releasing hormone and nociceptive
peptides (Tisljar, 1993; Kim et al., 2003).
Early literature was somewhat conflicting explicating the role
of the EP24.15 metalloenzyme in the etiology of AD. This enzyme
was originally erroneously thought to be the β-secretase activity
initiating the processing of the APP into Aβ (Papastoitsis et al.,
1994) prior to the discovery of the beta amyloid cleaving enzyme-
1 (BACE-1). The EP24.15 gene is located at a chromosomal locus
that is close to a region involved with early onset AD (Meckelein
et al., 1996). EP24.15 expression has been shown to inhibit the
toxicity of Aβ in vitro and to colocalize with Aβ plaques in an APP
transgenic mouse model of AD (Pollio et al., 2008). These studies
indicate that EP24.15 is potentially involved in the pathogenesis
of AD.
In addition to enzymes, carrier proteins play an important role
in Aβ clearance. One of these factors, transthyretin (TTR), was
first identified in a screen of cerebrospinal fluid (CSF) proteins
which were found to be capable of inhibiting Aβ fibrillogene-
sis (Schwarzman et al., 1994). Transthyretin is a homotetramer
consisting of four identical subunits of approximately 14 kD
each with detailed atomic structure elucidated by X-Ray crys-
tallography (Hörnberg et al., 2000). Transthyretin is known to
bind thyroid hormones and retinol binding protein in serum
(Schreiber and Richardson, 1997) suggestive of a role as a hor-
mone carrier protein with albumin-like qualities. Plasma TTR
is primarily synthesized in the liver while the choroid plexus
synthesizes TTR which is found abundantly in CSF making up
∼25% of total CSF proteins (Aldred et al., 1995). Transthyretin
can itself form amyloid under conditions in which the protein is
monomerized and partially unfolded (Kelly et al., 1997), however
at neutral to basic pH, it is extremely stable (Hammarström et al.,
2002).
Recent attention has focused on brain and CSF TTR as a
potential carrier for the clearance of Aβ peptide. Studies have
shown that expression of human TTR in C. elegans can rescue
behavior and pathology associated with expression of human Aβ
in muscle (Link, 1995). Moreover, transgenic mice that express
AD-related mutations exhibited accelerated rates of Aβ deposition
concomitant with hemizygous deletion of the TTR gene (Choi
et al., 2007) whereas overexpression of TTR suppressed patho-
logical and behavioral abnormalities associated with a transgenic
model of AD (Buxbaum et al., 2008). Recent evidence sug-
gests a potential positive-feedback regulation mechanism of APP
whereby increased generation of the APP intracellular domain
(AICD) leads to upregulation of Aβ clearing transcripts for TTR
and NEP (Kerridge et al., 2014).
In this work, we implement the integration of biophysical
results from molecular modeling, mass spectrometry, X-ray
crystallography, and Surface Plasmon Resonance (SPR) with
methods most often used to identify components of Aβ clearance.
We provide two examples, EP24.15, a neuropeptide processing
enzyme, and TTR, a carrier protein expressed in the CSF and
plasma that transports thyroid hormones and retinol. In this
manner, the progression from discovery to confirmation and
then validation can begin to vet interactors with Aβ for future
therapeutics to alter the equilibrium towards diminishing the
amyloid burden present in AD.
MATERIALS AND METHODS
EXPRESSION AND PURIFICATION OF Aβ-INTERACTING PROTEINS
EP24.15
Wild type EP24.15 was expressed and purified as previously
described (Cummins et al., 1999). In brief, BL21 Gold compe-
tent E. coli (Agilent, La Jolla, CA), transformed with pGEX2T-
EP24.15, was grown to OD600 = 0.8 and protein expression was
induced with 0.5 mM IPTG for 5 h at 16◦C. Pelleted cells were
resuspended in 100 mM Tris-HCl (pH 7.4) containing protease
inhibitor cocktail (Sigma, St Louis, MO) and passaged five times
through a French press homogenization cell followed by centrifu-
gation for 15 min at 14,000 ×g at 4◦C. The clarified extract was
bound for 4 h at 4◦C with rotation to Glutathione-Sepharose 4B
(GE Healthcare Life Sciences, Piscataway, NJ). The glutathione-
S-transferase tag was cleaved with thrombin (MP Biomedicals,
Santa Ana, CA) at 6 U/ml bed volume overnight at room temper-
ature. Wild type enzyme was eluted with 10 volumes of 100 mM
Tris-HCl (pH 7.4), concentrated with 30 kDa MWCO Amicon
Ultra centrifugal filters (Millipore, Billerica, MA) and the final
protein concentration adjusted to 5 mg/ml following Bradford
protein determination (Bio-Rad, Hercules, CA) and aliquoted for
storage at−80◦C until use. Sodium dodecyl sulfate acrylamide gel
electrophoresis (SDS-PAGE) was used to confirm enzyme purity
and quality.
TTR
The TTR open reading frame was cloned from a human cDNA
library (Molecular Biology and Genetics Core, University of
Chicago). For expression and purification, the eukaryotic signal
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sequence was deleted and an N-terminal 6-histidine tag was
cloned in its place. This construct was subcloned into the pProEx
bacterial expression vector and expressed by induction with
0.1 mM IPTG in the Rosetta (DE3) bacterial strain (EMD Mil-
lipore) for 16 h at 25◦C, conditions which preliminary expres-
sion experiments had demonstrated to be optimal for expression
and solubility of TTR. Analysis of the crude bacterial lysate by
Coomassie staining and Western immunoblot analyses indicated
robust expression and solubility of TTR. Based on this initial
expression, a large scale purification was performed in which
4 liters of media were inoculated and allowed to express for
24 h. Pelleted bacteria were resuspended in 250 mL lysate buffer
(20 mM Tris-Cl pH 7.7, 100 mM NaCl, 100 µM PMSF, 0.1 mg/mL
lysozyme), sonicated in lysate buffer and cleared of debris with a
low speed spin. The supernatant fraction was further centrifuged
at 100,000×g for 1 h and the supernatant containing soluble TTR
was collected. Transthyretin was purified from this fraction, first
by capture of the 6-His moiety on Ni-nitrilotriacetic acid (NTA)
resin, followed by anion exchange chromatography and then
precipitation of contaminants at 37◦C (Reixach et al., 2008). The
final TTR preparation using these methods was approximately
95% pure as judged by Coomassie staining of SDS-PAGE.
Since TTR is normally present as a homotetramer, samples
were submitted to native gel electrophoresis to assess the relative
mass. Transthyretin tetramers, with a calculated weight of 60 kD
with the His-tag, could be detected on silver-stained native PAGE
gels migrating just below bovine serum albumin (66 kD), indi-
cating that TTR was indeed tetrameric (Figure 4). The elution
profile of TTR preps submitted to size exclusion chromatogra-
phy indicated a size consistent with the previous results when
calculated against multiple standards (data not shown). Analysis
of preparations was performed using SDS-PAGE and subsequent
Western immunoblotting.
Aβ cleavage assay
To determine if EP24.15 cleaves Aβ 1–40 or Aβ 1–42 as potential
substrates, we incubated 300 µM Aβ peptide or neurotensin
(positive control) in the presence of 5 ng wild type EP24.15 in
25 mM Tris-HCl (pH 7.4), 125 mM NaCl, 1 mM DTT, and 2%
DMSO for various times up to 1 h at 37◦C. At the indicated times,
a 4 µl aliquot was removed from each reaction, diluted with 12 µl
of 10 mg/ml α-Cyano-4-hydroxycinnamic acid (CHCA, Sigma) in
60% acetonitrile/0.1% formic acid (Optima LCMS grade; Fisher
Scientific, Pittsburgh, PA).
Mass spectrometry and bioinformatics
Two microliters of the cleavage assay reaction was then spotted on
a MALDI plate. The dried samples were analyzed using a Voyager
DE STR mass spectrometer (AB Sciex, Framingham, MA) and
the resulting peaks were matched to Aβ fragments using Expasy’s
FindPept tool1. The following Voyager DE settings were used for
all samples: 200 laser shots per spot at 1870 J, 350–4700 Da mass
window with 350 Da low mass gate.
1http://web.expasy.org/findpept/
Transfection of EP24.15 into cell lines and western immunoblotting
Human recombinant EP24.15 was subcloned into a pcDNA3
vector containing a high-level transcription system (Invitrogen).
This construct was cotransfected into a M17 neuroblastoma
cell line already stably expressing APP containing the “Swedish”
mutation at the beta secretase site. The EP24.15 antibody was
used as described (Ferro et al., 1999; Massarelli et al., 1999) for
Western immunoblotting. For detection of Aβ, an N-terminal
antibody 3D6 (Elan Pharmaceuticals, South San Francisco, CA)
was utilized for detecting Aβ peptide.
TTR and Aβ co-immunoprecipitation
Because of the high insolubility of Aβ 1–42 and its propensity
for aggregation, all experiments were performed using Aβ 1–
40 peptides purchased from American Peptide Company. For
co-immunoprecipitation experiments, purified TTR and Aβ 1–40
peptides were combined in equimolar ratios in HEPES buffered
saline (50 mM HEPES pH 8.0, 150 mM NaCl) and allowed to
form complexes at 4◦C for 8 h. Complexes were captured by addi-
tion of rabbit anti-6His His-tag antibody (GenScript cat#A00174-
100) overnight at 4◦C after which the antibody was immobilized
with protein A Sepharose beads. In parallel, control preparation
included an antibody directed against at target unrelated to Aβ,
the protein BRI (Kim et al., 2002). Beads were washed five times
with HEPES buffered saline containing 0.05% Triton X-100 and
complexes were released by boiling in Laemmli sample buffer
prior to analysis by PAGE and Western blot. Amyloid-beta was
then detected using mouse monoclonal antibody 26D6 which
binds to the aa 1–12 of the Aβ peptide. Anti-BRI and 26D6
antibodies were a kind of gift of Sangram Sisodia (University of
Chicago).
Western immunoblotting of TTR
Samples were submitted to SDS-PAGE and transferred to
polyvinylidine fluoride membranes (Bio-Rad). Membranes were
washed in phosphate buffered saline containing 0.1% Tween20
(PBST) and blocked in PBST/5% milk for 1 h. After blocking,
membranes were incubated with primary antibodies for 3 h at
room temperature in PBST/1% milk washed three times in PBST
and incubated in HRP-conjugated secondary antibody (Thermo
Scientific) in PBST/1% milk for 1 h. For detection, blots were
washed four times in PBST followed by incubation in Super Signal
West Pico chemiluminescent substrate (Thermo Scientific) and
detected using a Bio-Rad XRS Chemidoc imager or autoradiog-
raphy film (Thermo Scientific).
Surface plasmon resonance
Surface plasmon resonance measurements were made using a
BIACORE3000 instrument (GE Healthcare Life Sciences). A pre-
conditioned Sensor Chip NTA (GE Healthcare Life Sciences) was
bound with Ni2+ solution at a speed of 20 µl/min. Tetrameric
His-tagged TTR was immobilized by flow of a 20 µM solution
in HBS-P buffer (10 mM HEPES pH 9.0, 0.15 M NaCl, 0.005%
Tween20, 0.5% DMSO) over the charged chip. The Aβ used was
dispersed into monomers from lyophilized aliquots using DMSO
before dilution into SPR binding buffer. For each concentration
of Aβ, the chip was stripped with imidazole and EDTA then
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recharged with TTR. All steps except for the Ni2+ binding step
were performed in a parallel channel of the Sensor Chip, and
these values were subtracted from the experimental channel to
obtain Response Unit (R.U.) values. Due to variability in results,
perhaps due to the hydrophobic nature of the Aβ peptide, the
experiment was repeated three times independently. The data
were analyzed using BiaEvaluation (Bio-Rad) software for curve
fitting.
RESULTS
NEUROPEPTIDE PROCESSING ENZYME EP24.15
Utilizing the model of the structure of the empty form of EP24.15
(Research Collaboratory for Structural Bioinformatics—Protein
Data Bank, entry 1S4B; Ray et al., 2004), Aβ 1–40 or Aβ 1–
42 could potentially interact in silico upon “closing” around the
substrate (data not shown) with subsequently cleaved peptide
products that can be subjected to amino and carboxypeptidases
for further degradation into smaller peptide fragments.
The first experimental confirmation of the putative Aβ degrad-
ing activity involved incubation of purified enzyme and Aβ 1–40
and 1–42 peptides in separate reactions. Cleavage reactions were
performed at t = 0’ and 30’ with Aβ 1–40 and Aβ 1–42 as
potential substrates (Figures 1A,B, respectively) under first order
kinetics and then subjected to matrix assisted laser desorption
ionization—time of flight (MALDI–TOF) mass spectrometry.
Cleaved fragments of Aβ peptide Aβ 1–40 (Table 1) and Aβ 1–42
(Table 2), respectively were processed using the known sequence
and their cleavage points mapped. Major cleavages are indicated
by the red arrows (Figure 1C).
Human recombinant EP24.15 was cotransfected into a model
of Aβ processing (Cai et al., 1993) consisting of human M17
neuroblastoma cells with full-length wild type APP or APP con-
taining the hyperprocessed “Swedish” mutation (KM 595/596
FIGURE 1 | Identification of major Aβ fragments by mass spectrometry
after incubation with EP24.15. (A) Mass Spectrum Aβ 1–40, (B) Mass
Spectrum Aβ 1–42, (C) Composite Major Cleavage Sites: Aβ 1–42.
Table 1 | Cleavage fragments of Aβ1–40.
Peptide Peptide Sequence
mass (Da) fragment
485.946 30–34 AIIGL
525.026 17–20 LVFF
672.661 27–33 NKGAIIG
1299.56 10–19 YEVHHQKLVF
2146.42 4–20 FRHDSGYEVHHQKLVFF
4329.82 1–40 DAEFRHDSGYEVHHQKLVFFAEDVGSNK
GAIIGLMVGGVV
Table 2 | Cleavage fragments of Aβ1–42.
Peptide Peptide Sequence
mass (Da) fragment
490.214 21–25 FAEDVG
525.026 17–20 LVFF
662.628 13–17 HHQKL
1299.56 10–19 YEVHHQKLVF
1315.74 26–39 SNKGAIIGLMVGGVVI
2146.42 4–20 FRHDSGYEVHHQKLVFF
2471.32 5–25 RHDSG YEVHHQKLVF FAEDVG
4514.10 1–42 DAEFRHDSGYEVHHQKLVFFAEDVGSNK
GAIIGLMVGGVVIA
NL). The amount of soluble products of Aβ ∼4 kD and
smaller was monitored via gel electrophoresis on a 16.5% gel.
Overexpression of EP24.15 was achieved in the APP “Swedish”
mutation background (Figure 2A) and the appearance of
smaller products was enhanced as well as with the sta-
bly transfected EP24.15 when blots were probed with the
N-terminally directed antibody (Figure 2B) in the background
of the “Swedish” mutation compared to the “Swedish” mutation
alone.
TRANSTHYRETIN
The expression of TTR in bacteria was assessed by comparing pre
and post induction with IPTG (Figure 3A). After isolation from
bacteria, lysates were purified utilizing fast performance protein
chromatography (FPLC) with affinity chromatography targeting
the His tag on TTR (Figure 3B). In solution, the complexes
assemble into a higher order tetramer as indicated by Native Gel
Electrophoresis (Figure 3C).
Direct interactions between TTR and Aβ were implicated by
co-immunoprecipitation (Co-IP) in a purified system containing
only TTR and Aβ. Thus, co-IP experiments were performed
in solution containing purified samples of both TTR and Aβ.
Transthyretin and Aβ were combined in equimolar ratios in
HEPES buffered saline and allowed to complex for 8 h at 4◦C
after which an anti-6-Histidine antibody or an unrelated anti-
body (anti-BRI antibody) was added to the solution followed by
overnight incubation. After a pulldown using Protein A beads,
Aβ was easily detectable by Western blot in the lane containing
the anti-His antibody (Figure 4A). A small amount of residual
Aβ was detected in the control lane, likely due to the fact that
Aβ’s hydrophobic properties allow for non-specific interactions
with the control antibody as well as the beads. Thus, TTR and
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FIGURE 2 | The effect of EP24.15 overexpression on Aβ metabolism
when co-transfected with cells expressing the “Swedish” mutation.
(A) M17 neuroblastoma cells transfected with APPsw and either mock
(Tx−) or EP24.15 (Tx+) and probed with an antibody for EP24.15. Western
immunoblotting on a 10% SDS-PAGE gel. (B) M17 neuroblastoma cells
transfected with either vector alone, APPsw or APPsw + EP24.15 and Aβ
and processed fragments probed with an N-terminal antibody for Aβ.
Western immunoblotting on a 16.5% SDS-PAGE gel.
FIGURE 3 | Expression and purification of TTR. (A) Expression of TTR.
Top, 12% acrylamide SDS-PAGE and Coomassie stain of pre- and
post-induction using IPTG. Bottom, Western blot of same samples with
specific detection of TTR using anit-His. (B) Purification of TTR using FPLC
and Ni2+ chromatography yielded pure TTR of approximately 95% purity as
indicated by 12% acrylamide SDS-PAGE and Coomassie staining. (C)
Purified sample run on 10% acrylamide Native-PAGE and stained by silver
staining. Relative migration rate of 59 kD indicative of tetramer assembly
was observed by native-PAGE whereas monomeric TTR is detected at
approximately 15 kD by denaturing electrophoresis (A and B).
Aβ can interact in purified solutions indicating a direct, binary
interaction.
Since TTR binds to Aβ in solution, formation of multimeric
Aβ (and by extension, insoluble fibrillar Aβ), would be inhibited
by its presence. To test this, purified TTR was incubated with
Aβ for 16 h at room temperature, and the formation of mul-
timeric Aβ species was assayed by native PAGE on Tris-glycine
pH 8.8 gels followed by transfer to polyvinylidene difluoride
FIGURE 4 | Co-immunoprecipitation and inhibition of Aβ multimer
formation. (A) Purified samples of TTR and Aβ were incubated in
HBS at equimolar ratios of 1 µM for 8 h at 4◦C after which
complexes were captured using anti-His or unrelated (anti-BRI)
antibody. Amyloid-beta was detected using monocolonal antibody
26D6 followed by 16.5% acrylamide tris-tricine SDS-PAGE. (B)
Amyloid-beta multimers form in the absence of TTR, but addition of
TTR to Aβ solution inhibits multimer formation as assessed by native
PAGE. Samples were run on 10% acrylamide gels using native-PAGE
at pH 8.8. Numbers to the left indicate relative molecular weight.
(PVDF) and Western blotting. With increasing TTR concen-
trations (Figure 4A, top panel), Aβ multimer formation was
reduced (Figure 4B, bottom panel). Monomeric species are not
detectable on this native gel, but separate analyses indicated that
proteolytic activity was not present (data not shown). Thus, TTR
was found to multimerize and inhibit the formation of high
molecular weight oligomeric Aβ species in a purified in vitro
system.
Next, we sought to determine the affinity of Aβ for TTR. To
accomplish this, we performed SPR experiments on purified TTR
and Aβ. Since the TTR purified for these experiments contains
a 6-His tag, we first utilized an NTA chip which coordinates
Ni2+ and allows binding of the 6-His tag. For these experiments,
NTA Sensor Chips were charged with Ni2+, bound with the TTR,
and Aβ was passed over the immobilized ligand. To account for
non-specific binding to the surface, all analyte samples are also
passed over a surface without ligand for a reference value which is
subtracted from the ligand channel to yield a Response Difference
value. Each step results in a change in the resonance units (RU)
monitored as a function of time. A typical experiment is depicted
on the sensorgram (Figure 5).
Using this paradigm, Aβ concentrations ranging from
2.5–50 µM were injected for 30 s followed by buffer alone for
30 s to measure the association/dissociation kinetics of Aβ to
immobilized TTR (O’Shannessy et al., 1994). After each con-
centration of Aβ, the chip was regenerated using imidazole and
EDTA and the cycle is repeated. An equal amount of TTR is
bound for each subsequent assay and three separate, independent
experiments were performed. The best fits using 1:1 Langmuir
binding formulas yielded an apparent kD within a similar range of
38 µM, 53 µM, and 98 µM for the three experiments (Figure 6A),
consistent with previous reports of TTR-Aβ affinities in which Aβ
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FIGURE 5 | Surface plasmon resonance protocol. Example of a single run
for SPR experiments. Ni2+ was used to charge NTA chips followed by His-TTR
binding to Ni2+–NTA. Amyloid-beta was then passed over the immobilized
TTR during which association and dissociation periods were recorded. After
each run, the chip was regenerated and the protocol was repeated with
another concentration of Aβ.
was immobilized on the SPR chips and TTR was injected (Li et al.,
2013).
To ensure that the TTR used in our experiments remained in a
tetrameric state, samples of TTR were removed from those used in
experiments at the conclusion of the SPR run. When fractionated
on native gels and stained with silver nitrate, only a single band
migrating at a Mr of ∼60 kD was detectable and no bands
were detectable at the monomeric mass of 15 kD. Thus, TTR
was indeed present in the functional tetrameric state throughout
the experiment. Another potential concern for the SPR experi-
ment is the propensity of Aβ to form aggregation structures in
solution. To ensure that Aβ remained in a non-aggregated state
throughout the experiment, samples of the solution containing
Aβ were taken at the completion of the experiments and ana-
lyzed for the presence of high-molecular weight structures using
SDS-PAGE (Rosen et al., 2010). No SDS-resistant Aβ multimers
were detectable when fractionated on tris-tricine SDS-PAGE gels
(Figure 6B—left lane) compared to an aged Aβ sample incubated
in the same buffer for 72 h in which SDS-resistant dimers are
present (Figure 6B—right lane).
DISCUSSION
By using a panoply of biophysical technology we can assess
interactors of Aβ peptide leading to its potential clearance and
reduce neuropathology associated with AD. We demonstrate two
potential interacting proteins that can affect the distribution of
neurotoxic Aβ: the neuropeptide processing enzyme EP24.15 and
carrier protein TTR.
EP24.15 has long been considered a factor in the etiology
of AD albeit in mistaken contexts. Prior to the discovery of
the transmembrane, aspartic acid protease, BACE, EP24.15 was
thought to be the β-secretase activity initiating the processing
of the APP into Aβ upon purification from human AD brains
(Papastoitsis et al., 1994) or from platelets and megakaryocytes
(Abraham et al., 1999). Subsequently, this group hypothesized
that the expression of EP24.15 induced Aβ degrading activity
in vitro through the stimulation/activation of an Aβ-degrading
serine proteinase activity (Yamin et al., 1999) from conditioned
medium from antisense transfected SKNMC neuroblastoma cell
line. An interaction with alpha 1-antichymotrypsin, elevated in
AD brain, and upregulation of serine proteases by EP24.15 was
hypothesized. However, our data supports a role for EP24.15 in
direct degradation of Aβ (Figure 1) that may occur concomi-
tantly with the upregulation of serine proteases. Earlier work
with synthetic peptides that spanned the beta secretase site at the
amino terminus of Aβ (not the entire Aβ peptide) demonstrated
cleavage by EP24.15, but this was not substantiated in vivo with
APP degradation (Papastoitsis et al., 1994; Thompson et al.,
1997).
By measuring the conversion of somatostatin 28 to somato-
statin 1–14 and the degradation of substance P (both substrates
of EP24.15), as poor, less specific surrogates for EP24.15 in the
temporal cortex, it was implied that regulation of EP24.15 was
significantly altered in AD (Waters and David, 1995; Waters and
Davis, 1997). When the activity of a panel of exo- and endopep-
tidases was surveyed in the frontal and parietal cortices as well as
cerebellums of patients diagnosed with AD there were reductions
observed with several enzymes including EP24.15 (Ichai et al.,
1994).
EP24.15 expression has been shown to inhibit the toxicity
of Aβ in vitro (Pollio et al., 2008). In older transgenic animals,
EP24.15 protein was increased in the hippocampus, support-
ive of a role in Aβ clearance though there was no attributable
mechanism. Interestingly, with regards to immunocytochemistry,
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FIGURE 6 | Transthyretin and Aβ. (A) Surface Plasmon Resonance
profiles of Aβ binding to immobilized TTR. Top—fits to data on bottom.
Experiment was repeated three times with apparent kD values ranging
from 35–98 µM. (B) Analysis by 10% acrylamide Native-PAGE and silver
stain of TTR samples used for SPR at completion sample input runs
indicated that TTR was stably present as a tetramer and was detected at
the expected relative mass of 59 kD. Similarly, Aβ used in SPR
experiments maintained its monomer form throughout the experiment,
and no SDS-resistant multimers were apparent by Western blot from
samples taken at the completion of the experiment, though multimers
are apparent in Aβ aged for 72 h in the same buffer as the TTR
experiments. MWM = molecular weight markers.
EP24.15 has been shown to localize in astrocytes and microglia
with double staining with glial fibrillary acidic protein and CD11b
markers respectively (Arif et al., 2009).
While, direct proteolytic degradation of Aβ is a critical part
of the clearance of this peptide, other modes of clearance are
also important. This includes interactions that affect the aggre-
gation of Aβ, as this is believed to be an essential step in its
neurotoxicity. An interaction between TTR and Aβ is posited
to occur based on evidence in vivo that TTR may play a role
in Aβ clearance. Co-immunoprecipitation of TTR and Aβ has
been performed in neural tissues (Buxbaum et al., 2008). While
it is apparent that TTR can affect Aβ fibrillization in vivo, direct
biochemical characterization of a TTR/Aβ complex has only
recently begun (Buxbaum et al., 2008; Li et al., 2013). Thus,
we sought to demonstrate that TTR can inhibit the formation
of oligomeric Aβ in systems containing only Aβ and TTR. Co-
immunoprecipitation can also be performed in vitro and we
further characterize a direct TTR/Aβ interaction by SPR. The
results are consistent with a role for TTR in the clearance
of Aβ from neuronal tissues. The affinities in the low micro-
molar range are consistent with previous reports for TTR/Aβ
interactions (Li et al., 2013), and considering the high con-
centration of TTR in CSF and plasma, are likely biologically
relevant for the binding and clearance of Aβ from interstitial
fluids.
Most recently, there appears to be epigenetic regulation of
both TTR and NEP, a peptidase closely related to EP24.15 (Ker-
ridge et al., 2014). The AICD has been shown to bind to the
NEP promoter upregulating transcriptional activation by histone
deacetylases with a concomitant increase in enzyme activity caus-
ing a potential increase in Aβ clearance. Taken together, these data
indicate that TTR and Aβ interact with low but detectable affinity
in the micromolar range in purified solutions and that TTR can
inhibit Aβ multimer formation consistent with findings in the
literature. Both of these effects are predicted to be protective from
AD pathology.
Utilizing approaches in the neuroma, such as identifying inter-
acting proteins that bind to APP or its neurotoxic products, can
aid in the development of effective pharmacological approaches
for patients afflicted by AD. As potential biomarkers, these targets
can aid in diagnosis and prognosis as well as treatment by increas-
ing clearance of Aβ.
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